The BioCentury Show

Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets

On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Ba

Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient

The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could event

Ep. 116 - Ovid's Jeremy Levin on biotech in the balance

Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jer

Ep. 115 - Initiate's Owens on what it takes to be AI-native

As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intracta

Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than a

Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking

Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad allianc

Ep. 112 - Chris Arendt on rebuilding Takeda for AI

Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living t

Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner

ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting clo

Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China

Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an act

Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational

Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy

A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to

Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing

The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth t

Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform

The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem

Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers

As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury

Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity

There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of

Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development

Caution: This episode of The BioCentury Show contains strong language. In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that sta

Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs

With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and t

Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms

Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage o

Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next

Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capi

Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma

In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxie